,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBXUA0'}, 'Id': 'a0P2P000005SmBXUA0', 'Event_Date__c': '2018-11-11', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArZRQA0'}, 'change': None}]",Nov 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBYUA0'}, 'Id': 'a0P2P000005SmBYUA0', 'Event_Date__c': '2019-10-14', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000B2I4QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBZUA0'}, 'Id': 'a0P2P000005SmBZUA0', 'Event_Date__c': '2019-11-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2019', 'Status_History__c': 'a132P000000BBc5QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that oral sirolimus for the treatment of severe non-malignant lymphovascular malformations be funded with a high priority. </p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with non-malignant vascular malformations, the limited effective and acceptable standard treatment options, and the benefit of sirolimus on disease management through lesion shrinkage and quality of life improvement. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to sirolimus for this indication is appropriate as there is an identifiable patient population with lymphovascular malformations currently funded via the Named Patient Pharmaceutical Assessment (NPPA) pathway, and listing may help to ensure ongoing supply of sirolimus for suitable patients and alleviate the administrative burden for clinicians. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus for the treatment of lymphovascular malformations should be listed subject to the following Special Authority criteria:</p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Initial application – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient has severe non-malignant lymphovascular malformation; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3. Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4. Patient has measurable disease as defined by RECIST version 1.1 (see Note).</span></p><p><br></p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Renewal – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 12 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.\xa0\xa0\xa0\xa0Patient’s disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.\xa0\xa0\xa0\xa0Either:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Both:</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.1\xa0\xa0\xa0\xa0\xa0Patient has measurable disease as defined by RECIST version 1.1; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.2\xa0\xa0\xa0\xa0\xa0Patient’s disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0No evidence of progressive disease according to RECIST criteria (see Note); and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0The treatment remains clinically appropriate and the patient is benefitting from the treatment.</span></p><p style=""text-align: justify;"">\t</p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST)</span><span style=""font-size: 9pt; color: black;""> version 1.1 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/19097774-new-response-evaluation-criteria-in-solid-tumours-revised-recist-guideline-version-11/"" target=""_blank"" style=""font-size: 9pt;"">Eisenhauer et al. Eur J Cancer 2009;45:228-47</a></p><p><br></p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that oral sirolimus for the treatment of severe non-malignant lymphovascular malformations be funded with a high priority. </p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with non-malignant vascular malformations, the limited effective and acceptable standard treatment options, and the benefit of sirolimus on disease management through lesion shrinkage and quality of life improvement. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to sirolimus for this indication is appropriate as there is an identifiable patient population with lymphovascular malformations currently funded via the Named Patient Pharmaceutical Assessment (NPPA) pathway, and listing may help to ensure ongoing supply of sirolimus for suitable patients and alleviate the administrative burden for clinicians. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus for the treatment of lymphovascular malformations should be listed subject to the following Special Authority criteria:</p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Initial application – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient has severe non-malignant lymphovascular malformation; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3. Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4. Patient has measurable disease as defined by RECIST version 1.1 (see Note).</span></p><p><br></p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Renewal – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 12 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.\xa0\xa0\xa0\xa0Patient’s disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.\xa0\xa0\xa0\xa0Either:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Both:</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.1\xa0\xa0\xa0\xa0\xa0Patient has measurable disease as defined by RECIST version 1.1; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.2\xa0\xa0\xa0\xa0\xa0Patient’s disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0No evidence of progressive disease according to RECIST criteria (see Note); and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0The treatment remains clinically appropriate and the patient is benefitting from the treatment.</span></p><p style=""text-align: justify;"">\t</p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST)</span><span style=""font-size: 9pt; color: black;""> version 1.1 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/19097774-new-response-evaluation-criteria-in-solid-tumours-revised-recist-guideline-version-11/"" target=""_blank"" style=""font-size: 9pt;"">Eisenhauer et al. Eur J Cancer 2009;45:228-47</a></p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is a T cell inhibitor which forms a complex that inhibits the mTOR pathway, blocking several signal transduction pathways including the PI3K/AKT pathway, leading to inhibition of lymphocyte activation and increased immunosuppression. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is Medsafe-approved for prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants, and that it is listed in the Pharmaceutical Schedule as rescue therapy for an organ transplant recipient. Members considered that sirolimus use for transplant recipients represents a small patient group and that patients funded via NPPA for other uses represent a reasonable portion of its funded use.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PHARMAC has previously considered funding of sirolimus for individual patients for the treatment of lymphovascular malformations secondary to different underlying conditions (such as Klippel-Trenaunay Syndrome (KTS), Blue Rubber Nevus, Gorham-Stout disease and lymphatic malformation) through the Named Patient Pharmaceutical Assessment (NPPA) pathway.</p><p><b>3.5.1</b><b style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</b><b>[Withheld]</b></p><p>3.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients considered under NPPA typically had lesions throughout the abdomen, pelvis, lower limbs and cervicofacial areas resulting in deformity, bleeding, pain and difficulties with movement, swallowing and/or breathing.</p><p>3.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the patient group considered for funding through NPPA is expected to represent less than 10 patients per year, being those with extensive and severe disease, with a history of sclerotherapy and/or previous debulking procedures, and lesions not considered amenable to further surgery. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant estimates less than 5 patients per year would be suitable for treatment with sirolimus for lymphovascular malformations. The Committee considered that lymphovascular malformations are rare and considered that patient numbers would be highly dependent on disease definitions used. Members noted that Starship Children’s Hospital in Auckland facilitates regular multi-disciplinary meetings where cases of lymphovascular malformations are discussed.</p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current genotypic definitions (eg. identifiable somatic or germline PIK3CA signalling pathway mutation) and phenotypic definitions (eg. patient did not receive a response from prior therapies) are not mutually inclusive and are unable to accurately define all patients with lymphovascular malformations, such as some patients assessed via NPPA. Members considered that patients with lymphovascular malformation are difficult to define but clinically recognisable. </p><p>3.7.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that this genotypic definition may include patients beyond the intended group, because PI3K mutation is common. Members noted that PI3K mutation would likely be detected in between 20% to 50% of patients with lymphovascular malformations according to variable phenotypic definitions. </p><p>3.7.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that patients with Kaposiform Haemangioendothelioma, Blue Rubber Bleb Naevus Syndrome and other lymphovascular malformations (entities described as PIK3CA-Related Overgrowth Spectrum (PROS) by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25557259"" target=""_blank"" style=""color: windowtext;"">Keppler-Noreuil et al. Am J Med Genet A. 2015;167A(2):287-95)</a> should be considered within this population.</p><p>3.7.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the common characteristics of the applicant-defined patient groups were lesions arising from lymphovascular tissue and occurrence in children. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment options for lymphovascular malformations include observation, sclerotherapy, symptomatic management, laser therapy and surgical options such as debulking and/or total resection. However, some of these interventions may have limited benefit, result in scar tissue and can lead to regrowth of lesions. Members considered that lymphovascular malformations can present an airway risk, making intubation for surgical treatment not feasible.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that surgical debulking is not appropriate for patients with widespread/extensive malformations, and although surgical management addresses the consequence of lymphatic malformation it has no impact on the underlying cause, with patients typically requiring several surgeries. The Committee noted that risks of surgical debulking include cosmetic deformity, fistula formation, vascular damage and nerve injury. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with lymphovascular malformations were a broad, varied group with a high health need, although the specific health need of individuals would depend on the location, size and rate of change of lesions. The Committee noted evidence that patients with vascular malformations have lower quality of life (QOL) scores for physical, body pain, social functioning and mental health domains compared to the general population (<a href=""https://pubmed.ncbi.nlm.nih.gov/29562060-vascular-malformations-and-health-related-quality-of-life-a-systematic-review-and-meta-analysis/?from_term=Vascular+Malformations+and+Health-Related+Quality+of+Life%3A+A+Systematic+Review+and+Meta-analysis&amp;from_pos=1"" target=""_blank"">Nguyen et al. JAMA Dermatol. 2018:154;661-9</a>). Members considered that family members of patients with lymphovascular malformations would have a health need due to stress associated with a chronically ill child or family member.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary evidence submitted by the applicant was a phase II, open-label study investigating the efficacy and safety of sirolimus (0.8 mg/m<sup>2</sup> twice daily, guided to target trough levels of 10-15 ng/ml) for complicated vascular anomalies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. Pediatrics. 2016;137(2):e20153257</a>). The Committee noted that the study included 57 patients aged 0 to 31 years with a diagnosed vascular anomaly and at least 1 of 6 predefined complications. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of this study was response according to an aggregate of clinical criteria and functional impairment, quality of life (QOL), and radiologic assessment using either the Response Evaluation in Solid Tumour (RECIST) criteria or modified RECIST. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, although no participants had a complete response, 85% had a partial response at the end of course 12 (each course defined as 28 days) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"" style=""color: windowtext;"">Adams et al. 2016</a>). Members considered this aggregate primary endpoint was useful although it is a non-validated, study-specific measure.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted other evidence from retrospective and prospective reviews. Each of these reports involved 20 or fewer participants with lymphatic anomalies/lymphovascular malformations and reported a surrogate of response rate (RR) to sirolimus, usually defined by RECIST, which varied from 50% to 80% or higher (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. Pediatr Blood Centre. 2019;66:</a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">:e27614</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31196128"" target=""_blank"">Ozeki et al. Orphanet J Rare Dis. 2019;14:141</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27723921"" target=""_blank"">Triana et al. Eur J Pediatr Surg. 2017;27:86-90</a>). </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a retrospective review of 19 patients treated with sirolimus for cervicofacial lymphovascular malformation, which reported that 6 patients developed cellulitis and 4 patients had bleeding throughout treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=28782106"" target=""_blank"">Strychowsky et al. Laryngoscope. 2018;128:269-76</a>). The Committee noted that 12 patients stopped sirolimus therapy and of these, 7 experienced recurrence of symptoms and resumed treatment. </p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for sirolimus supports a tumour-shrinking effect, however, the optimal duration of treatment and whether therapy should be ongoing or intermittent remains unknown. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that some adverse effects (AEs), eg. bleeding and thrombotic events, occur soon after treatment and are likely reported in the evidence, however, long-term AEs such as ulceration, hemiplegia or organ impacts may occur over a much longer period eg. 10 to 15 years, and would not be evident in the available evidence.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the safety profile of sirolimus includes AEs such as bleeding, thrombosis, delayed wound healing, skin malignancies, hypersensitivity, infections, hyperlipidaemia, renal insufficiency and proteinuria (<a href=""https://www.medsafe.govt.nz/Profs/Datasheet/r/Rapamunetaboralsoln.pdf"" target=""_blank"">Rapamune Data Sheet. Medsafe [Internet]. 2012 [Updated September 2019]).</a> Members considered that suppression of platelets in the bone marrow can occur with sirolimus, eg. when used in bone marrow transplant patients, and trough drug concentration monitoring may be required. The Committee noted that the Medsafe data sheet states blood trough concentrations of sirolimus are generally maintained between 4-12 ng/mL (for transplant indication) and that co-treatment with medicines with CYP3A interactions should be avoided where possible, otherwise additional monitoring of drug levels may be required.</p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a prospective review of 20 patients receiving sirolimus for lymphatic abnormalities that reported a statistically significant improvement in QOL (<i>p</i>=0.0105) from pre-treatment to 6 months in the entire patient cohort (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31196128"" target=""_blank"">Ozeki et al. 2019</a>), and a retrospective review of 18 patients receiving sirolimus for generalised lymphatic anomaly and Gorham-Stout disease that reported a QOL improvement in 78% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. 2019</a>). The Committee noted that the quality of life (QOL) data for sirolimus in the treatment of lymphovascular malformations generally comes from uncontrolled reviews and case reports that use a variety of measurement tools.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the available evidence does not report decreases in disease-related adverse events (AEs) and that the focus of the evidence was lesion size. The Committee considered that the evidence was of poor to moderate quality, and was subject to inevitable bias due to the limitations of their study methods, coming primarily from individual case reports, including publication bias. The Committee considered that there is a strong biologic rationale for use of sirolimus in the treatment of lymphovascular malformations in patients with molecularly defined disease, however, there is no evidence from prospective clinical trials designed to investigate its use in this patient population.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the available evidence suggests treatment that results in a response improves QOL in patients with lymphovascular malformations. </p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus would likely offer benefit to patients who have already undertaken local therapies such as surgery and sclerotherapy, however, sirolimus may be used earlier in treatment. Members considered sirolimus may be preferable to invasive treatment options eg surgical debulking; however, members considered that sirolimus may simply be used earlier in the treatment paradigm for the same patient population, resulting in no increase to the patient numbers receiving sirolimus. </p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that tumour shrinkage with sirolimus may facilitate anaesthesia and future sclerotherapy in patients, and that pre-operative treatment with sirolimus for malformation reduction could also lead to better outcomes after surgery, especially in children.</p><p>3.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that the fiscal risks associated with funding sirolimus for the treatment of lymphovascular malformations were small, given its limited use in organ transplant recipients and known adverse effects, and considered that the risk of use in patients out of scope of the Special Authority criteria was small. </p><p>3.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the funding of sirolimus may require additional testing and visits (for therapeutic drug monitoring and toxicity monitoring), and prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia (PJP) with twice-weekly cotrimoxazole. Members considered that if a genotypic definition were used for Special Authority criteria, an additional biopsy and molecular testing may be required. </p><p>3.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the dynamic, evolving patient group with lymphovascular malformations could not be accurately defined based on current evidence and considered that the definition of this patient group would change over time as more data becomes available. The Committee considered that a pragmatic population definition of lymphovascular malformation based on clinical phenotype and failure to respond adequately to prior therapies could be suitable to use for funding criteria, and that a requirement for genetic testing was not a suitable criterion based on current evidence. </p><p>3.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a refined definition of the appropriate patient population and a specific outcome, such as the aggregated response outcome used by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. 2016</a> or a response based on conventional RECIST assessment, should be used to model cost-effectiveness. Members noted that RECIST assessments are challenging to perform in clinical practice due to resource requirements and complexity. Members considered that RECIST assessments may be performed informally, which could result in difficulties auditing compliance with funding restrictions.</p><p>3.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee commented that this had been a complex and challenging application to consider, further complicated by some overlap in the scope of funding considerations for medicines for rare disorders with limited evidence, and the need to define eligible populations suitable for the Pharmaceutical Schedule.\xa0</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is a T cell inhibitor which forms a complex that inhibits the mTOR pathway, blocking several signal transduction pathways including the PI3K/AKT pathway, leading to inhibition of lymphocyte activation and increased immunosuppression. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is Medsafe-approved for prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants, and that it is listed in the Pharmaceutical Schedule as rescue therapy for an organ transplant recipient. Members considered that sirolimus use for transplant recipients represents a small patient group and that patients funded via NPPA for other uses represent a reasonable portion of its funded use.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PHARMAC has previously considered funding of sirolimus for individual patients for the treatment of lymphovascular malformations secondary to different underlying conditions (such as Klippel-Trenaunay Syndrome (KTS), Blue Rubber Nevus, Gorham-Stout disease and lymphatic malformation) through the Named Patient Pharmaceutical Assessment (NPPA) pathway.</p><p><b>3.5.1</b><b style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</b><b>[Withheld]</b></p><p>3.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients considered under NPPA typically had lesions throughout the abdomen, pelvis, lower limbs and cervicofacial areas resulting in deformity, bleeding, pain and difficulties with movement, swallowing and/or breathing.</p><p>3.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the patient group considered for funding through NPPA is expected to represent less than 10 patients per year, being those with extensive and severe disease, with a history of sclerotherapy and/or previous debulking procedures, and lesions not considered amenable to further surgery. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant estimates less than 5 patients per year would be suitable for treatment with sirolimus for lymphovascular malformations. The Committee considered that lymphovascular malformations are rare and considered that patient numbers would be highly dependent on disease definitions used. Members noted that Starship Children’s Hospital in Auckland facilitates regular multi-disciplinary meetings where cases of lymphovascular malformations are discussed.</p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current genotypic definitions (eg. identifiable somatic or germline PIK3CA signalling pathway mutation) and phenotypic definitions (eg. patient did not receive a response from prior therapies) are not mutually inclusive and are unable to accurately define all patients with lymphovascular malformations, such as some patients assessed via NPPA. Members considered that patients with lymphovascular malformation are difficult to define but clinically recognisable. </p><p>3.7.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that this genotypic definition may include patients beyond the intended group, because PI3K mutation is common. Members noted that PI3K mutation would likely be detected in between 20% to 50% of patients with lymphovascular malformations according to variable phenotypic definitions. </p><p>3.7.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that patients with Kaposiform Haemangioendothelioma, Blue Rubber Bleb Naevus Syndrome and other lymphovascular malformations (entities described as PIK3CA-Related Overgrowth Spectrum (PROS) by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25557259"" target=""_blank"" style=""color: windowtext;"">Keppler-Noreuil et al. Am J Med Genet A. 2015;167A(2):287-95)</a> should be considered within this population.</p><p>3.7.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the common characteristics of the applicant-defined patient groups were lesions arising from lymphovascular tissue and occurrence in children. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment options for lymphovascular malformations include observation, sclerotherapy, symptomatic management, laser therapy and surgical options such as debulking and/or total resection. However, some of these interventions may have limited benefit, result in scar tissue and can lead to regrowth of lesions. Members considered that lymphovascular malformations can present an airway risk, making intubation for surgical treatment not feasible.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that surgical debulking is not appropriate for patients with widespread/extensive malformations, and although surgical management addresses the consequence of lymphatic malformation it has no impact on the underlying cause, with patients typically requiring several surgeries. The Committee noted that risks of surgical debulking include cosmetic deformity, fistula formation, vascular damage and nerve injury. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with lymphovascular malformations were a broad, varied group with a high health need, although the specific health need of individuals would depend on the location, size and rate of change of lesions. The Committee noted evidence that patients with vascular malformations have lower quality of life (QOL) scores for physical, body pain, social functioning and mental health domains compared to the general population (<a href=""https://pubmed.ncbi.nlm.nih.gov/29562060-vascular-malformations-and-health-related-quality-of-life-a-systematic-review-and-meta-analysis/?from_term=Vascular+Malformations+and+Health-Related+Quality+of+Life%3A+A+Systematic+Review+and+Meta-analysis&amp;from_pos=1"" target=""_blank"">Nguyen et al. JAMA Dermatol. 2018:154;661-9</a>). Members considered that family members of patients with lymphovascular malformations would have a health need due to stress associated with a chronically ill child or family member.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary evidence submitted by the applicant was a phase II, open-label study investigating the efficacy and safety of sirolimus (0.8 mg/m<sup>2</sup> twice daily, guided to target trough levels of 10-15 ng/ml) for complicated vascular anomalies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. Pediatrics. 2016;137(2):e20153257</a>). The Committee noted that the study included 57 patients aged 0 to 31 years with a diagnosed vascular anomaly and at least 1 of 6 predefined complications. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of this study was response according to an aggregate of clinical criteria and functional impairment, quality of life (QOL), and radiologic assessment using either the Response Evaluation in Solid Tumour (RECIST) criteria or modified RECIST. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, although no participants had a complete response, 85% had a partial response at the end of course 12 (each course defined as 28 days) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"" style=""color: windowtext;"">Adams et al. 2016</a>). Members considered this aggregate primary endpoint was useful although it is a non-validated, study-specific measure.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted other evidence from retrospective and prospective reviews. Each of these reports involved 20 or fewer participants with lymphatic anomalies/lymphovascular malformations and reported a surrogate of response rate (RR) to sirolimus, usually defined by RECIST, which varied from 50% to 80% or higher (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. Pediatr Blood Centre. 2019;66:</a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">:e27614</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31196128"" target=""_blank"">Ozeki et al. Orphanet J Rare Dis. 2019;14:141</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27723921"" target=""_blank"">Triana et al. Eur J Pediatr Surg. 2017;27:86-90</a>). </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a retrospective review of 19 patients treated with sirolimus for cervicofacial lymphovascular malformation, which reported that 6 patients developed cellulitis and 4 patients had bleeding throughout treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=28782106"" target=""_blank"">Strychowsky et al. Laryngoscope. 2018;128:269-76</a>). The Committee noted that 12 patients stopped sirolimus therapy and of these, 7 experienced recurrence of symptoms and resumed treatment. </p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for sirolimus supports a tumour-shrinking effect, however, the optimal duration of treatment and whether therapy should be ongoing or intermittent remains unknown. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that some adverse effects (AEs), eg. bleeding and thrombotic events, occur soon after treatment and are likely reported in the evidence, however, long-term AEs such as ulceration, hemiplegia or organ impacts may occur over a much longer period eg. 10 to 15 years, and would not be evident in the available evidence.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the safety profile of sirolimus includes AEs such as bleeding, thrombosis, delayed wound healing, skin malignancies, hypersensitivity, infections, hyperlipidaemia, renal insufficiency and proteinuria (<a href=""https://www.medsafe.govt.nz/Profs/Datasheet/r/Rapamunetaboralsoln.pdf"" target=""_blank"">Rapamune Data Sheet. Medsafe [Internet]. 2012 [Updated September 2019]).</a> Members considered that suppression of platelets in the bone marrow can occur with sirolimus, eg. when used in bone marrow transplant patients, and trough drug concentration monitoring may be required. The Committee noted that the Medsafe data sheet states blood trough concentrations of sirolimus are generally maintained between 4-12 ng/mL (for transplant indication) and that co-treatment with medicines with CYP3A interactions should be avoided where possible, otherwise additional monitoring of drug levels may be required.</p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a prospective review of 20 patients receiving sirolimus for lymphatic abnormalities that reported a statistically significant improvement in QOL (<i>p</i>=0.0105) from pre-treatment to 6 months in the entire patient cohort (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31196128"" target=""_blank"">Ozeki et al. 2019</a>), and a retrospective review of 18 patients receiving sirolimus for generalised lymphatic anomaly and Gorham-Stout disease that reported a QOL improvement in 78% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. 2019</a>). The Committee noted that the quality of life (QOL) data for sirolimus in the treatment of lymphovascular malformations generally comes from uncontrolled reviews and case reports that use a variety of measurement tools.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the available evidence does not report decreases in disease-related adverse events (AEs) and that the focus of the evidence was lesion size. The Committee considered that the evidence was of poor to moderate quality, and was subject to inevitable bias due to the limitations of their study methods, coming primarily from individual case reports, including publication bias. The Committee considered that there is a strong biologic rationale for use of sirolimus in the treatment of lymphovascular malformations in patients with molecularly defined disease, however, there is no evidence from prospective clinical trials designed to investigate its use in this patient population.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the available evidence suggests treatment that results in a response improves QOL in patients with lymphovascular malformations. </p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus would likely offer benefit to patients who have already undertaken local therapies such as surgery and sclerotherapy, however, sirolimus may be used earlier in treatment. Members considered sirolimus may be preferable to invasive treatment options eg surgical debulking; however, members considered that sirolimus may simply be used earlier in the treatment paradigm for the same patient population, resulting in no increase to the patient numbers receiving sirolimus. </p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that tumour shrinkage with sirolimus may facilitate anaesthesia and future sclerotherapy in patients, and that pre-operative treatment with sirolimus for malformation reduction could also lead to better outcomes after surgery, especially in children.</p><p>3.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that the fiscal risks associated with funding sirolimus for the treatment of lymphovascular malformations were small, given its limited use in organ transplant recipients and known adverse effects, and considered that the risk of use in patients out of scope of the Special Authority criteria was small. </p><p>3.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the funding of sirolimus may require additional testing and visits (for therapeutic drug monitoring and toxicity monitoring), and prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia (PJP) with twice-weekly cotrimoxazole. Members considered that if a genotypic definition were used for Special Authority criteria, an additional biopsy and molecular testing may be required. </p><p>3.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the dynamic, evolving patient group with lymphovascular malformations could not be accurately defined based on current evidence and considered that the definition of this patient group would change over time as more data becomes available. The Committee considered that a pragmatic population definition of lymphovascular malformation based on clinical phenotype and failure to respond adequately to prior therapies could be suitable to use for funding criteria, and that a requirement for genetic testing was not a suitable criterion based on current evidence. </p><p>3.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a refined definition of the appropriate patient population and a specific outcome, such as the aggregated response outcome used by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. 2016</a> or a response based on conventional RECIST assessment, should be used to model cost-effectiveness. Members noted that RECIST assessments are challenging to perform in clinical practice due to resource requirements and complexity. Members considered that RECIST assessments may be performed informally, which could result in difficulties auditing compliance with funding restrictions.</p><p>3.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee commented that this had been a complex and challenging application to consider, further complicated by some overlap in the scope of funding considerations for medicines for rare disorders with limited evidence, and the need to define eligible populations suitable for the Pharmaceutical Schedule.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a clinician application for oral sirolimus for the treatment of lymphovascular malformations.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a clinician application for oral sirolimus for the treatment of lymphovascular malformations.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBaUAK'}, 'Id': 'a0P2P000005SmBaUAK', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Feb 2020', 'Published_Recommendation__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that oral sirolimus for the treatment of severe non-malignant lymphovascular malformations be funded with a high priority. </p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with non-malignant vascular malformations, the limited effective and acceptable standard treatment options, and the benefit of sirolimus on disease management through lesion shrinkage and quality of life improvement. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to sirolimus for this indication is appropriate as there is an identifiable patient population with lymphovascular malformations currently funded via the Named Patient Pharmaceutical Assessment (NPPA) pathway, and listing may help to ensure ongoing supply of sirolimus for suitable patients and alleviate the administrative burden for clinicians. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus for the treatment of lymphovascular malformations should be listed subject to the following Special Authority criteria:</p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Initial application – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient has severe non-malignant lymphovascular malformation; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and</span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3. Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and </span></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4. Patient has measurable disease as defined by RECIST version 1.1 (see Note).</span></p><p><br></p><p><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">Renewal – </b><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">(severe non-malignant lymphovascular malformations)</span><b style=""font-family: Arial, sans-serif; font-size: 9pt;""> </b></p><p><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Approvals valid for 12 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.\xa0\xa0\xa0\xa0Patient’s disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.\xa0\xa0\xa0\xa0Either:</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2 Both:</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.1\xa0\xa0\xa0\xa0\xa0Patient has measurable disease as defined by RECIST version 1.1; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.2.2\xa0\xa0\xa0\xa0\xa0Patient’s disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0No evidence of progressive disease according to RECIST criteria (see Note); and</span></p><p style=""text-align: justify;"">\t<span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0The treatment remains clinically appropriate and the patient is benefitting from the treatment.</span></p><p style=""text-align: justify;"">\t</p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST)</span><span style=""font-size: 9pt; color: black;""> version 1.1 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/19097774-new-response-evaluation-criteria-in-solid-tumours-revised-recist-guideline-version-11/"" target=""_blank"" style=""font-size: 9pt;"">Eisenhauer et al. Eur J Cancer 2009;45:228-47</a></p><p><br></p>', 'Published_Application__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a clinician application for oral sirolimus for the treatment of lymphovascular malformations.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is a T cell inhibitor which forms a complex that inhibits the mTOR pathway, blocking several signal transduction pathways including the PI3K/AKT pathway, leading to inhibition of lymphocyte activation and increased immunosuppression. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that sirolimus is Medsafe-approved for prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants, and that it is listed in the Pharmaceutical Schedule as rescue therapy for an organ transplant recipient. Members considered that sirolimus use for transplant recipients represents a small patient group and that patients funded via NPPA for other uses represent a reasonable portion of its funded use.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PHARMAC has previously considered funding of sirolimus for individual patients for the treatment of lymphovascular malformations secondary to different underlying conditions (such as Klippel-Trenaunay Syndrome (KTS), Blue Rubber Nevus, Gorham-Stout disease and lymphatic malformation) through the Named Patient Pharmaceutical Assessment (NPPA) pathway.</p><p><b>3.5.1</b><b style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</b><b>[Withheld]</b></p><p>3.5.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients considered under NPPA typically had lesions throughout the abdomen, pelvis, lower limbs and cervicofacial areas resulting in deformity, bleeding, pain and difficulties with movement, swallowing and/or breathing.</p><p>3.5.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the patient group considered for funding through NPPA is expected to represent less than 10 patients per year, being those with extensive and severe disease, with a history of sclerotherapy and/or previous debulking procedures, and lesions not considered amenable to further surgery. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant estimates less than 5 patients per year would be suitable for treatment with sirolimus for lymphovascular malformations. The Committee considered that lymphovascular malformations are rare and considered that patient numbers would be highly dependent on disease definitions used. Members noted that Starship Children’s Hospital in Auckland facilitates regular multi-disciplinary meetings where cases of lymphovascular malformations are discussed.</p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current genotypic definitions (eg. identifiable somatic or germline PIK3CA signalling pathway mutation) and phenotypic definitions (eg. patient did not receive a response from prior therapies) are not mutually inclusive and are unable to accurately define all patients with lymphovascular malformations, such as some patients assessed via NPPA. Members considered that patients with lymphovascular malformation are difficult to define but clinically recognisable. </p><p>3.7.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that this genotypic definition may include patients beyond the intended group, because PI3K mutation is common. Members noted that PI3K mutation would likely be detected in between 20% to 50% of patients with lymphovascular malformations according to variable phenotypic definitions. </p><p>3.7.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that patients with Kaposiform Haemangioendothelioma, Blue Rubber Bleb Naevus Syndrome and other lymphovascular malformations (entities described as PIK3CA-Related Overgrowth Spectrum (PROS) by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/25557259"" target=""_blank"" style=""color: windowtext;"">Keppler-Noreuil et al. Am J Med Genet A. 2015;167A(2):287-95)</a> should be considered within this population.</p><p>3.7.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the common characteristics of the applicant-defined patient groups were lesions arising from lymphovascular tissue and occurrence in children. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that current treatment options for lymphovascular malformations include observation, sclerotherapy, symptomatic management, laser therapy and surgical options such as debulking and/or total resection. However, some of these interventions may have limited benefit, result in scar tissue and can lead to regrowth of lesions. Members considered that lymphovascular malformations can present an airway risk, making intubation for surgical treatment not feasible.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that surgical debulking is not appropriate for patients with widespread/extensive malformations, and although surgical management addresses the consequence of lymphatic malformation it has no impact on the underlying cause, with patients typically requiring several surgeries. The Committee noted that risks of surgical debulking include cosmetic deformity, fistula formation, vascular damage and nerve injury. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with lymphovascular malformations were a broad, varied group with a high health need, although the specific health need of individuals would depend on the location, size and rate of change of lesions. The Committee noted evidence that patients with vascular malformations have lower quality of life (QOL) scores for physical, body pain, social functioning and mental health domains compared to the general population (<a href=""https://pubmed.ncbi.nlm.nih.gov/29562060-vascular-malformations-and-health-related-quality-of-life-a-systematic-review-and-meta-analysis/?from_term=Vascular+Malformations+and+Health-Related+Quality+of+Life%3A+A+Systematic+Review+and+Meta-analysis&amp;from_pos=1"" target=""_blank"">Nguyen et al. JAMA Dermatol. 2018:154;661-9</a>). Members considered that family members of patients with lymphovascular malformations would have a health need due to stress associated with a chronically ill child or family member.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary evidence submitted by the applicant was a phase II, open-label study investigating the efficacy and safety of sirolimus (0.8 mg/m<sup>2</sup> twice daily, guided to target trough levels of 10-15 ng/ml) for complicated vascular anomalies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. Pediatrics. 2016;137(2):e20153257</a>). The Committee noted that the study included 57 patients aged 0 to 31 years with a diagnosed vascular anomaly and at least 1 of 6 predefined complications. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary endpoint of this study was response according to an aggregate of clinical criteria and functional impairment, quality of life (QOL), and radiologic assessment using either the Response Evaluation in Solid Tumour (RECIST) criteria or modified RECIST. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, although no participants had a complete response, 85% had a partial response at the end of course 12 (each course defined as 28 days) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"" style=""color: windowtext;"">Adams et al. 2016</a>). Members considered this aggregate primary endpoint was useful although it is a non-validated, study-specific measure.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted other evidence from retrospective and prospective reviews. Each of these reports involved 20 or fewer participants with lymphatic anomalies/lymphovascular malformations and reported a surrogate of response rate (RR) to sirolimus, usually defined by RECIST, which varied from 50% to 80% or higher (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. Pediatr Blood Centre. 2019;66:</a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">:e27614</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/31196128"" target=""_blank"">Ozeki et al. Orphanet J Rare Dis. 2019;14:141</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27723921"" target=""_blank"">Triana et al. Eur J Pediatr Surg. 2017;27:86-90</a>). </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a retrospective review of 19 patients treated with sirolimus for cervicofacial lymphovascular malformation, which reported that 6 patients developed cellulitis and 4 patients had bleeding throughout treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=28782106"" target=""_blank"">Strychowsky et al. Laryngoscope. 2018;128:269-76</a>). The Committee noted that 12 patients stopped sirolimus therapy and of these, 7 experienced recurrence of symptoms and resumed treatment. </p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for sirolimus supports a tumour-shrinking effect, however, the optimal duration of treatment and whether therapy should be ongoing or intermittent remains unknown. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that some adverse effects (AEs), eg. bleeding and thrombotic events, occur soon after treatment and are likely reported in the evidence, however, long-term AEs such as ulceration, hemiplegia or organ impacts may occur over a much longer period eg. 10 to 15 years, and would not be evident in the available evidence.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the safety profile of sirolimus includes AEs such as bleeding, thrombosis, delayed wound healing, skin malignancies, hypersensitivity, infections, hyperlipidaemia, renal insufficiency and proteinuria (<a href=""https://www.medsafe.govt.nz/Profs/Datasheet/r/Rapamunetaboralsoln.pdf"" target=""_blank"">Rapamune Data Sheet. Medsafe [Internet]. 2012 [Updated September 2019]).</a> Members considered that suppression of platelets in the bone marrow can occur with sirolimus, eg. when used in bone marrow transplant patients, and trough drug concentration monitoring may be required. The Committee noted that the Medsafe data sheet states blood trough concentrations of sirolimus are generally maintained between 4-12 ng/mL (for transplant indication) and that co-treatment with medicines with CYP3A interactions should be avoided where possible, otherwise additional monitoring of drug levels may be required.</p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a prospective review of 20 patients receiving sirolimus for lymphatic abnormalities that reported a statistically significant improvement in QOL (<i>p</i>=0.0105) from pre-treatment to 6 months in the entire patient cohort (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31196128"" target=""_blank"">Ozeki et al. 2019</a>), and a retrospective review of 18 patients receiving sirolimus for generalised lymphatic anomaly and Gorham-Stout disease that reported a QOL improvement in 78% of patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/30672136"" target=""_blank"">Ricci et al. 2019</a>). The Committee noted that the quality of life (QOL) data for sirolimus in the treatment of lymphovascular malformations generally comes from uncontrolled reviews and case reports that use a variety of measurement tools.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the available evidence does not report decreases in disease-related adverse events (AEs) and that the focus of the evidence was lesion size. The Committee considered that the evidence was of poor to moderate quality, and was subject to inevitable bias due to the limitations of their study methods, coming primarily from individual case reports, including publication bias. The Committee considered that there is a strong biologic rationale for use of sirolimus in the treatment of lymphovascular malformations in patients with molecularly defined disease, however, there is no evidence from prospective clinical trials designed to investigate its use in this patient population.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the available evidence suggests treatment that results in a response improves QOL in patients with lymphovascular malformations. </p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that sirolimus would likely offer benefit to patients who have already undertaken local therapies such as surgery and sclerotherapy, however, sirolimus may be used earlier in treatment. Members considered sirolimus may be preferable to invasive treatment options eg surgical debulking; however, members considered that sirolimus may simply be used earlier in the treatment paradigm for the same patient population, resulting in no increase to the patient numbers receiving sirolimus. </p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that tumour shrinkage with sirolimus may facilitate anaesthesia and future sclerotherapy in patients, and that pre-operative treatment with sirolimus for malformation reduction could also lead to better outcomes after surgery, especially in children.</p><p>3.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that the fiscal risks associated with funding sirolimus for the treatment of lymphovascular malformations were small, given its limited use in organ transplant recipients and known adverse effects, and considered that the risk of use in patients out of scope of the Special Authority criteria was small. </p><p>3.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the funding of sirolimus may require additional testing and visits (for therapeutic drug monitoring and toxicity monitoring), and prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia (PJP) with twice-weekly cotrimoxazole. Members considered that if a genotypic definition were used for Special Authority criteria, an additional biopsy and molecular testing may be required. </p><p>3.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the dynamic, evolving patient group with lymphovascular malformations could not be accurately defined based on current evidence and considered that the definition of this patient group would change over time as more data becomes available. The Committee considered that a pragmatic population definition of lymphovascular malformation based on clinical phenotype and failure to respond adequately to prior therapies could be suitable to use for funding criteria, and that a requirement for genetic testing was not a suitable criterion based on current evidence. </p><p>3.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that a refined definition of the appropriate patient population and a specific outcome, such as the aggregated response outcome used by <a href=""https://www.ncbi.nlm.nih.gov/pubmed/26783326"" target=""_blank"">Adams et al. 2016</a> or a response based on conventional RECIST assessment, should be used to model cost-effectiveness. Members noted that RECIST assessments are challenging to perform in clinical practice due to resource requirements and complexity. Members considered that RECIST assessments may be performed informally, which could result in difficulties auditing compliance with funding restrictions.</p><p>3.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee commented that this had been a complex and challenging application to consider, further complicated by some overlap in the scope of funding considerations for medicines for rare disorders with limited evidence, and the need to define eligible populations suitable for the Pharmaceutical Schedule.\xa0</p>', 'Status_History__c': 'a132P000000BV3tQAG'}, 'change': None}]",Oct 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBbUAK'}, 'Id': 'a0P2P000005SmBbUAK', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BV4OQAW'}, 'change': None}]",Feb 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2020', 'fs': 'Mar 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBcUAK'}, 'Id': 'a0P2P000005SmBcUAK', 'Event_Date__c': '2020-03-03', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2020', 'Status_History__c': 'a132P000000BwsHQAS'}, 'change': None}]",Mar 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-10-02-sirolimus/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-10-02-sirolimus/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2020', 'fs': 'Oct 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBdUAK'}, 'Id': 'a0P2P000005SmBdUAK', 'Event_Date__c': '2020-10-07', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-10-02-sirolimus/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Oct 2020', 'Status_History__c': 'a132P000000CEiUQAW'}, 'change': None}]",Oct 2020,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2020', 'fs': 'Oct 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBeUAK'}, 'Id': 'a0P2P000005SmBeUAK', 'Event_Date__c': '2020-10-20', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2020', 'Status_History__c': 'a132P000000CH6TQAW'}, 'change': None}]",Oct 2020,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2020-12-23-sirolimus/?type=Decision&amp;page=1', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2020-12-23-sirolimus/?type=Decision&amp;page=1', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2021', 'fs': 'Jan 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005SmBfUAK'}, 'Id': 'a0P2P000005SmBfUAK', 'Event_Date__c': '2021-01-22', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2020-12-23-sirolimus/?type=Decision&amp;page=1', 'Formatted_Date__c': 'Jan 2021', 'Status_History__c': 'a132P000000CX5HQAW'}, 'change': None}]",Jan 2021,False,True
